Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Intima Bioscience, Inc.
Essen Biotech
University of California, Davis
Alaunos Therapeutics
Hadassah Medical Organization
Vall d'Hebron Institute of Oncology
Essen Biotech
National Cancer Institute (NCI)
Fate Therapeutics
Fate Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
BGI, China
Second Affiliated Hospital of Soochow University
PACT Pharma, Inc.
Genocea Biosciences, Inc.
University of California, Davis
Roger Williams Medical Center